SERPINB2 and cancer: These include (1) increased procoagulant factors (for example, tissue factor, cancer procoagulant), (2) reduced anticoagulant factors (for example, antithrombin, protein C, protein S, tissue factor pathway inhibitor), (3) altered fibrinolysis through elevated plasminogen activator inhibitor, (4) expression of tissue factor and cytokines, which activate coagulation cascade, (for example, tumor necrosis factor, interleukin 1 and 6) [8].